JAMA Editors' Summary
Activehealthfitnessmedicinescience

JAMA Editors' Summary

by JAMA Network

Insights from recent episode analysis

Audience Interest

Estimated Reach: 50,001 - 70,000
Listeners across platforms

Podcast Focus

Categories: health · fitness
+2 more

Publishing Consistency

Frequency: Irregular
950+ episodes since 2006

Platform Reach

Insights are generated by CastFox AI using publicly available data, episode content, and proprietary models.

High Confidence

Est. Listeners

50,001 - 70,000

Based on iTunes & Spotify (publisher stats).

  • Per-Episode Audience

    Est. listeners per new episode within ~30 days

    25,001 - 50,000
  • Monthly Reach

    Unique listeners across all episodes (30 days)

    75,001 - 150,000
  • Active Followers

    Loyal subscribers who consistently listen

    40,001 - 100,000

Market Insights

This ShowCategory Avg
No category insights available.
📡

Platform Distribution

Reach across major podcast platforms, updated hourly

Total Followers

Total Plays

Total Reviews

YouTube

YouTube

Subscribers

Views

Videos

Castbox

Castbox

Followers

Plays

Reviews

Podcast App

Podcast App

Followers

Plays

Reviews

Podcast Republic

Podcast Republic

Followers

Plays

Reviews

TuneIn

TuneIn

Followers

Plays

Reviews

* Data sourced directly from platform APIs and aggregated hourly across all major podcast directories.

On the show

Recent episodes

Symptom-Based Dosing for Neonatal Opioid Withdrawal, Chronic Pain Management for Veterans, MMA Embolization for Chronic Subdural Hematoma, and more

May 1, 2026

Unknown duration

Rapid Antimicrobial Susceptibility Testing for Gram-Negative Bacteremia, Neurocognitive Outcomes in Severe Childhood Malaria, Amoxicillin-Clavulanate for Adult Acute Sinusitis, and more

Apr 24, 2026

Unknown duration

Transcatheter Tricuspid Valve Replacement Outcomes, Tobramycin for Surgical Site Infection in Tibial Fracture, AI Drug Prescribing, and more

Apr 17, 2026

Unknown duration

Discontinuing Levothyroxine in Older Adults, Cost-Effectiveness of Laboratory Goals for Lipid-Lowering Therapy, CRC Screening for Older Adults and more

Apr 10, 2026

Unknown duration

Evolocumab for Reducing MACE, Lead Exposure and CVD, AI Scribes for Clinicians, and more

Apr 3, 2026

Unknown duration

🔗

Social Links & Contact

Official channels & resources

🌐

Official Website

Login

📡

RSS Feed

Login

Chart Positions

13 placements across 12 markets.